• slidebg1

    "Abingworth was the original lead investor in SFJ and has since made 5 additional investments
    in SFJ related companies. Working together to maximize the full potential growth and sustainability of SFJ,
    we have formed a true partnership with the Abingworth team."

    Robert DeBenedetto, President and CEO of SFJ Pharmacecuticals

Clinical Co-development

We have pioneered a new approach to partnering with pharmaceutical and biotech companies to help them develop effective new drugs and deliver them to patients in an accelerated manner. This creative model, called Clinical Co-development, provides finance for late-stage therapeutic assets with the co-development company incurring all of the clinical and regulatory risk. The co-development company receives a pre-negotiated return once the drug is approved.

Abingworth has raised a $105 million fund dedicated to investing in Clinical Co-development that will co-invest with other Abingworth funds.

Why is it attractive to Pharma?

  • Off-balance sheet financing
  • Faster execution of clinical trials
  • Higher quality of clinical data

Case Studies

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Clinical Co-development

We have pioneered a new approach to partnering with pharmaceutical and biotech companies to help them develop effective new drugs and deliver them to patients in an accelerated manner. This creative model, called Clinical Co-development, provides finance for late-stage therapeutic assets with the co-development company incurring all of the clinical and regulatory risk. The co-development company receives a pre-negotiated return once the drug is approved.

Abingworth has raised a $105 million fund dedicated to investing in Clinical Co-development that will co-invest with other Abingworth funds.

Why is it attractive to Pharma?

  • Off-balance sheet financing
  • Faster execution of clinical trials
  • Higher quality of clinical data

Case Studies

 
Copyright Abingworth 2017